Percutaneous Cryoablation of Liver Tumors: Initial Experience from a Tertiary Care Center in India.
BCLC, Barcelona Clinic Liver Cancer
CA, Cryoablation
CT, Computed Tomography
HCC, Hepatocellular Carcinoma
LTP, Local Tumor Progression
MWA, Microwave Ablation
RFA, Radiofrequency Ablation
US, Ultrasound
ablation
cryoablation
hepatocellular carcinoma
Journal
Journal of clinical and experimental hepatology
ISSN: 0973-6883
Titre abrégé: J Clin Exp Hepatol
Pays: India
ID NLM: 101574137
Informations de publication
Date de publication:
Historique:
received:
26
05
2020
accepted:
12
10
2020
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
ppublish
Résumé
Percutaneous ablation is an important part of management strategy for liver tumors. While radiofrequency ablation and microwave ablation are the most widely used ablative techniques, cryoablation (CA) has several technical advantages but has been underused till recently. In this study, we report the initial experience with percutaneous CA of liver tumors. This was a retrospective evaluation of consecutive patients with liver tumors who underwent percutaneous CA between October 2018 and August 2019. The ablation procedures were performed under combined ultrasound and computed tomography guidance using argon-helium-based CA systems. The baseline tumor characteristics (including size and location), Barcelona Clinic Liver Cancer stage, and Child-Pugh score were recorded. Each patient underwent a follow-up after 1 month and at 3 months subsequently. Technical success, complete response, local tumor progression, and overall survival were evaluated. Nine patients (mean age, 62.4 years, median age, 66 years, five men and four women) with 10 liver tumors (mean size, 2.22 cm) underwent CA. Seven (77.8%) patients had hepatocellular carcinoma (HCC), and 2 patients had solitary liver metastasis. One patient with HCC had two lesions, while the rest had only one lesion. Of the two metastatic lesions, one was from carcinoma of the cervix and the other was from jejunal neuroendocrine tumor. Five tumors were located adjacent to the gallbladder, two lesions were adjacent to the right portal vein, two lesions were subcapsular, and one lesion was adjacent to the stomach. Technical success was achieved in all the patients. Complete response was achieved in 7 (77.8%) patients. The median follow-up period was 7 months (range, 3-12 months). There was no local tumor progression and no death during the follow-up period. No procedure-related complication was seen. Percutaneous CA of hepatic tumors is technically feasible and is a safe and effective ablative technique.
Sections du résumé
BACKGROUND
BACKGROUND
Percutaneous ablation is an important part of management strategy for liver tumors. While radiofrequency ablation and microwave ablation are the most widely used ablative techniques, cryoablation (CA) has several technical advantages but has been underused till recently. In this study, we report the initial experience with percutaneous CA of liver tumors.
METHODS
METHODS
This was a retrospective evaluation of consecutive patients with liver tumors who underwent percutaneous CA between October 2018 and August 2019. The ablation procedures were performed under combined ultrasound and computed tomography guidance using argon-helium-based CA systems. The baseline tumor characteristics (including size and location), Barcelona Clinic Liver Cancer stage, and Child-Pugh score were recorded. Each patient underwent a follow-up after 1 month and at 3 months subsequently. Technical success, complete response, local tumor progression, and overall survival were evaluated.
RESULTS
RESULTS
Nine patients (mean age, 62.4 years, median age, 66 years, five men and four women) with 10 liver tumors (mean size, 2.22 cm) underwent CA. Seven (77.8%) patients had hepatocellular carcinoma (HCC), and 2 patients had solitary liver metastasis. One patient with HCC had two lesions, while the rest had only one lesion. Of the two metastatic lesions, one was from carcinoma of the cervix and the other was from jejunal neuroendocrine tumor. Five tumors were located adjacent to the gallbladder, two lesions were adjacent to the right portal vein, two lesions were subcapsular, and one lesion was adjacent to the stomach. Technical success was achieved in all the patients. Complete response was achieved in 7 (77.8%) patients. The median follow-up period was 7 months (range, 3-12 months). There was no local tumor progression and no death during the follow-up period. No procedure-related complication was seen.
CONCLUSION
CONCLUSIONS
Percutaneous CA of hepatic tumors is technically feasible and is a safe and effective ablative technique.
Identifiants
pubmed: 33994713
doi: 10.1016/j.jceh.2020.10.005
pii: S0973-6883(20)30155-9
pmc: PMC8103339
doi:
Types de publication
Journal Article
Langues
eng
Pagination
305-311Informations de copyright
© 2020 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.
Références
Ann Surg Oncol. 2015 Apr;22(4):1294-300
pubmed: 25287439
J Hepatocell Carcinoma. 2016 Oct 05;3:41-53
pubmed: 27785449
Int J Hyperthermia. 2019;36(1):264-272
pubmed: 30676100
Diagn Interv Radiol. 2020 Jan;26(1):34-39
pubmed: 31650975
Diagn Interv Radiol. 2020 Mar;26(2):111-117
pubmed: 32071029
Br J Surg. 2002 Dec;89(12):1613-9
pubmed: 12445075
Cardiovasc Intervent Radiol. 2019 Apr;42(4):584-590
pubmed: 30697637
Clin Mol Hepatol. 2016 Dec;22(4):509-515
pubmed: 28081593
J Korean Surg Soc. 2011 Jul;81(1):25-34
pubmed: 22066097
Oncotarget. 2016 Aug 23;7(34):55368-55376
pubmed: 27421135
Arch Surg. 2002 Dec;137(12):1332-9; discussion 1340
pubmed: 12470093
PLoS One. 2015 Apr 07;10(4):e0123065
pubmed: 25849963
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Arch Surg. 2000 Jun;135(6):657-62; discussion 662-4
pubmed: 10843361
Hepatogastroenterology. 2013 Jul-Aug;60(125):1131-5
pubmed: 23321123
Diagn Interv Radiol. 2010 Mar;16(1):90-5
pubmed: 19998248
Medicine (Baltimore). 2015 Dec;94(49):e2252
pubmed: 26656371
Hepatology. 2015 May;61(5):1579-90
pubmed: 25284802
Insights Imaging. 2019 May 20;10(1):53
pubmed: 31111237
J Vasc Interv Radiol. 2020 Mar;31(3):393-400.e1
pubmed: 31987705
World J Radiol. 2015 Oct 28;7(10):306-18
pubmed: 26516427
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Int J Hyperthermia. 2016 May;32(3):339-44
pubmed: 26794414